Upstream Bio's selloff may be 'overdone,' but analyst highlights asthma drug's competitive edge concerns

Upstream Bio Inc. UPB shares are trading lower during Friday’s session as the stock reacts to recent developments in its clinical trials. Over the last few days, the stock has plunged more than 54%.
Fierce Biotech

Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario

A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...

Upstream Bio shows asthma drug cuts attacks by 56%, stock reacts

Upstream Bio, Inc. UPB shares were trading higher during Wednesday’s premarket session following positive results from the Phase 2 VALIANT trial of verekitug, a treatment for severe asthma. The stock ...

Upstream Bio’s stock drops 47% on verekitug Phase II asthma data

Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma ...

Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data

Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.